<div><p><b>Background: </b>Providers at community hospitals often seek to transfer hospitalized patients with advanced liver disease to tertiary/quaternary care hospitals for further management due to lack of expertise in caring for these patients. However, it is possible to co-manage such patients at local hospitals by providing virtual consultation by tertiary care hepatologists via inpatient telehepatology (INP-TH) consultation.

<div><p><strong>Background</strong>: <span data-contrast="none" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW199784672 BCX0"><span class="NormalTextRun SCXW199784672 BCX0" data-ccp-charstyle="x_x_normaltextrun">Outcomes of adults with ZZ alpha-1-antitrypsin deficiency (AATD) liver disease is variable and unpredictable. There is a lack of prospective data, including on the utility of liver biopsy.

<div><p><b>Background:</p> </b><p>Metabolic dysfunction-associated steatohepatitis (MASH) patients who have developed stage F4 fibrosis (cirrhosis) are at risk of hepatic decompensation, hepatocellular carcinoma, liver transplant, cardiovascular events, liver and all-cause mortality. There are currently no approved therapies for non-cirrhotic or cirrhotic MASH.</p>

<div><p><b>Background: </b>Studies on incident liver and cardiovascular outcomes in lean (body mass index: BMI &lt;25 kg/m², or &lt;23 kg/m² for Asians) vs. non-lean individuals with metabolic dysfunction-associated steatohepatitis (MASH) have reported mixed results. We aimed to compare incident clinical outcomes and mortality between lean and non-lean individuals with compensated MASH cirrhosis in a large national cohort.</p>

<div><p><b>Background: </b>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease in the US. Notably, disease prevalence differs greatly by race/ethnicity, with the highest prevalence in those of Hispanic and Asian ancestry, and the lowest prevalence in those of African ancestry. To date, studies have identified common variants associated with MASLD in predominantly European or American populations.

<div><p><b>Background:<span> </b>Progressive familial intrahepatic cholestasis (PFIC) are a group of recessive disorders linked by the inability to appropriately excrete bile salts (BS) from hepatocytes. PFIC1 results from mutations in <em>ATP8B1 </em>encoding FIC1, an apical membrane aminophospholipid translocase.

<div><p><b>Background:</p> </b><div><p><span lang="EN-US">In the context of alcohol-related liver disease (ArLD), changes in the homeostasis of the gut-liver axis have become a focus of major </span></p></div>

<div><p><b>Background:</p> </b><p>Acute variceal bleeding (AVB) is a cause of serious morbidity and mortality in cirrhosis. While more severe disease (e.g. higher Child-Turcotte-Pugh [CTP] score) has been shown to correlate with worse outcomes after AVB, it is unclear if this correlation remains universal across all cirrhosis etiologies.

<div><p><strong>Background</strong>: Minimal hepatic encephalopathy (MHE) is associated with poor outcomes but treatment strategies are limited. Rifamycin SV MMX (RiVM) is a novel rifampin derivative which a non-absorbable antibiotic with maximal impact in the colon. <u>Aim</u>: Evaluate impact of RiVM on microbiome, safety &amp; gut-brain axis in an RCT.</p>

<div><p><strong>Background</strong>: Regional differences in environment, health-care system, microbiology lab capabilities, countermeasures of drug resistance may greatly impact the occurrence and evolution of infection in cirrhosis. We aimed to assess the prevalence, characteristics, clinical impact, and variations in infection on admission (AdI) across a global population of cirrhosis inpatients.</p>